Alpha Tau Medical

Company Overview

Snapshot

Founded in January 2016 by Prof. Itzhak Kelson and Prof. Yona Keisari, Alpha Tau Medical operates with 51–200 employees. The company has raised $201.9M across 7 funding rounds from 10 investors. In May 2026, Alpha Tau Medical completed patient enrollment in its U.S. pivotal skin cancer study, advancing towards FDA approval of Alpha DaRT® to treat recurrent Cutaneous Squamous Cell Carcinoma.

Business overview

Alpha Tau Medical is a medical device company focused on developing and commercializing its Diffusing Alpha-emitters Radiation Therapy (DaRT) for treating solid cancers. Its core technology, developed at Tel Aviv University, utilizes alpha-emitting atoms directly inserted into tumors to deliver a high-energy dose over several millimeters, providing focal alpha-radiation that spares surrounding healthy tissue. The company serves the oncology market, specifically targeting various solid cancers including skin, head and neck, breast, pancreas, lung, and glioblastoma multiforme, operating within the Health Tech & Life Sciences sector.

Strategic signal

In May 2026, Alpha Tau Medical completed patient enrollment in its U.S. pivotal skin cancer study for its Alpha DaRT® treatment. This milestone is crucial for the company as it signifies a major step towards potential FDA approval for recurrent Cutaneous Squamous Cell Carcinoma, indicating strong progress in its clinical development pipeline and validating its therapeutic approach for a significant patient population.

Company Intelligence Q&A

What is Alpha Tau Medical's primary therapeutic focus?

Alpha Tau Medical focuses on the development and commercialization of its Diffusing Alpha-emitters Radiation Therapy (DaRT) for the treatment of solid cancers.

When did Alpha Tau Medical complete patient enrollment for its U.S. pivotal skin cancer study?

In May 2026, Alpha Tau Medical completed patient enrollment in its U.S. pivotal skin cancer study, moving closer to FDA approval of Alpha DaRT® for recurrent Cutaneous Squamous Cell Carcinoma.

Has Alpha Tau Medical received any FDA designations for its Alpha DaRT technology?

Yes, Alpha Tau Medical received FDA Breakthrough Device Designation for Alpha DaRT for the treatment of patients with SCC of the skin or oral cavity without curative standard of care, and later for the treatment of recurrent Glioblastoma Multiforme.

When did Alpha Tau Medical treat its first patient in the U.S. multi-center pancreatic cancer clinical trial?

In September 2025, Alpha Tau Medical successfully treated its first patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial.

What was a significant recent development regarding Alpha Tau Medical's manufacturing capabilities?

In October 2025, Alpha Tau Medical announced the receipt of a Radioactive Material License for its New Hampshire Manufacturing Facility, advancing towards commercial readiness.